Vireo Growth VREOF Q2 2026 10-Q: Cannabis 280E Tax Charged $41.6M, Paid $1.0M
Listen to this report
RoboSystems Cannabis Coverage · Q2 FY2026 Form 10-Q, filed August 14, 2026 (accession 0001104659-26-097118, CIK 0001771706) · every figure verified live against the RoboSystems SEC graph unless attributed otherwise · priced August 14, 2026
The Hook
Last quarter we initiated coverage on Vireo Growth $VREOF and wrote that the company "paid roughly forty-two million dollars of cash income taxes in a year it never earned a pretax profit." Going back to the cash flow statement for this update, that sentence was wrong. The correction is the whole story.
Vireo's current income tax expense for 2025 was $41.6 million. Income taxes paid, net, for the same year, from the supplemental cash flow disclosure in the same filing: $1.0 million. In the first half of 2026, current tax expense was $38.3 million and cash taxes paid were $6.2 million. Vireo is not being bled by Section 280E. It is charging itself the tax, taking a disputed position, and keeping the cash. The unpaid balance sits on the June 30 balance sheet as a $172.8 million uncertain tax liability, up from $120.0 million at year end, and it is classified as a current liability. Vireo holds $103.1 million of unrestricted cash.
That reclassification changes what kind of company this is. Operating cash flow for the six months was positive $14.3 million. Inside that number, the increase in unpaid uncertain tax positions was an add-back of $29.8 million. Take it out and operations consumed $15.5 million of cash. The single largest source of funds behind the fastest roll-up in American cannabis is a tax bill it has booked and not paid.
Company Snapshot
Vireo Growth is a British Columbia registrant that files a US 10-Q. Through its Cannabis segment it cultivated, manufactured and sold in ten states during Q2 2026: California, Colorado, Florida, Maryland, Minnesota, Missouri, Nevada, New Mexico, New York and Utah. In April and June it bought two businesses that are not cannabis at all, Hawthorne (hydroponic nutrients and lighting, from Scotts Miracle-Gro) and Bridgewell (organic and non-GMO food ingredients), and created a second reportable segment around them. A 30-for-1 share consolidation took effect June 5, 2026, so every per-share figure here and in the filing is post-consolidation.
Announced and pending deals, per company press releases and not the filing, take the pro forma footprint to roughly 265 dispensaries across 15 states and a stated run rate above $1 billion, which would make Vireo the largest US operator by dispensary count. The filing itself covers ten states and $209.3 million of quarterly revenue. Keep the two straight.
The Financial Story
The growth is real and it is enormous. Revenue went from $48.1 million in Q2 2025 to $209.3 million in Q2 2026, up 335 percent. Gross profit went from $20.4 million to $95.3 million. Then the operating line goes the wrong way.
| Q2, three months ended June 30 | 2025 | 2026 |
|---|---|---|
| Revenue | $48.1M | $209.3M |
| Gross profit | $20.4M | $95.3M |
| Operating expenses | $22.4M | $101.6M |
| Operating income (loss) | ($2.0M) | ($6.3M) |
| Pretax income (loss) | ($10.1M) | $14.2M |
| Net loss | ($14.9M) | ($0.1M) |
Source: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, GrossProfit, OperatingExpenses, OperatingIncomeLoss, IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, NetIncomeLoss; Q2 FY2026 10-Q, undimensioned.
Four and a third times the revenue produced a wider operating loss. And the segment note shows the money is not being lost in the operations. Cannabis segment operating income was positive $21.0 million in the quarter; Non-Cannabis was negative $0.1 million; the two segments together earned $20.9 million. Consolidated operating income was negative $6.3 million. The $27.2 million gap is corporate cost that sits below both segments, and $19.7 million of it is transaction-related expense for one quarter of deal-making.
The reported pretax profit of $14.2 million is not operating profit either. It exists because of a $21.7 million bargain purchase gain on Hawthorne. Read why, in the company's own words: the gain arose "primarily because the Hawthorne Shares were valued for accounting purposes based on the Company's closing share price of $11.79 immediately prior to the acquisition date, which was lower than the $18.00 deemed price per share negotiated by the parties." Vireo agreed to hand over stock worth $18.00 a share. The market said the stock was worth $11.79. GAAP records the cheaper number, and the difference becomes income. The worse Vireo's stock performs between signing and closing, the larger the accounting gain on the deal. Strip the gain out and Q2 pretax is negative $7.5 million.
Now the tax. This is where the prior brief needs correcting, and where the balance sheet gets interesting.
| Income tax: charged vs paid | FY2024 | FY2025 | H1 2026 |
|---|---|---|---|
| Current income tax expense | $11.1M | $41.6M | $38.3M |
| Income taxes paid, net (cash) | n/d | $1.0M | $6.2M |
| Uncertain tax liability, period end | $120.0M | $172.8M |
Source: us-gaap:CurrentIncomeTaxExpenseBenefit, us-gaap:IncomeTaxesPaidNet, vreof:UncertainTaxLiabilityCurrent; FY2025 10-K and Q2 FY2026 10-Q.
Of the $52.8 million increase in the liability, $23.0 million came in with Eaze on April 1 and is matched by a $23.0 million indemnification asset from Eaze's former stockholders. The other $29.8 million is Vireo's own accrual, and it is the exact add-back that makes operating cash flow positive. Total indemnified assets on the balance sheet are $48.8 million, so the net unindemnified back-tax exposure is roughly $124 million against $103.1 million of cash.
Vireo did take the new relief. Effective April 23, 2026, following the medical-only Schedule III order, management concluded at a more-likely-than-not level that an apportioned share of SG&A attributable to medical activity is deductible, and stopped treating it as an uncertain position going forward. The filing is candid about how load-bearing that judgment is: it "involves significant estimation and judgment in the absence of formal Treasury or IRS guidance, which is expected but has not yet been issued," and revisions "could result in a material adjustment to the Company's income tax provision in future periods." Meanwhile the current tax expense barely moved as a share of revenue: 10.0 percent of revenue in Q2 2025, 9.6 percent in Q2 2026. Partial relief arrived and, one quarter in, it is close to invisible.
Catalyst Scenarios: How the Math Changes
How the roll-up was actually paid for, and my correction to the setup. The obvious thesis for a company like this is debt-funded empire building. The filing says otherwise. Of $264.1 million of consideration transferred in the first half, $202.1 million was non-cash, which is to say stock. Shares outstanding went from 35.24 million at December 31 to 45.04 million at June 30, and 48.82 million on an as-converted basis at the filing date. Deals already signed add roughly 16.8 million more: about 11 million shares for the four Ohio transactions, about 5.2 million for Planet 13 at the stated 0.015383618 exchange ratio against Planet 13's own 335.3 million shares outstanding, and 645,161 for PhytoNatural. That is another 34 percent of the current count, before 1.09 million options, 2.10 million RSUs, 3.18 million compensation warrants and the Eaze earnout. Debt did roughly double, from $143.9 million to $298.8 million of long-term debt plus $23.6 million of convertibles, but dilution is the larger currency by a wide margin.
The non-cannabis segment is a financing vehicle, not a diversification. This is the most interesting thing in the filing and nobody is writing about it. On August 7, 2026, disclosed as a subsequent event, Vireo's non-cannabis subsidiaries closed a five-year senior secured asset-based revolver led by Bank of Montreal, $65 million initially and expandable to $105 million, at Term SOFR plus 1.75 to 2.00 percent. In the same document, the cannabis business is paying 15 percent on the seller note it took from Innovative Industrial Properties to buy its New York facility, prime plus 5.75 percent on the second mortgage behind it, and 12 percent on two other Chicago Atlantic facilities.
| What Vireo pays to borrow | Rate | Lender |
|---|---|---|
| Non-cannabis ABL revolver | SOFR + 1.75-2.00% | Bank of Montreal (agent) |
| First lien term loan | SOFR (3% floor) + 4% | East West Bank / Western Alliance |
| Chicago Atlantic second lien | Prime (7.5% floor) + 5.5% | Chicago Atlantic |
| Perth mortgage, second lien | Prime + 5.75% | Chicago Atlantic |
| Perth seller note | 15.0% | Innovative Industrial Properties |
Source: Notes 11 and 23, Q2 FY2026 10-Q. Rates as stated in the filing.
That is roughly a 700 to 900 basis point spread inside one consolidated group, separated only by whether the borrower touches the plant. Buying a garden-supply distributor and a food-ingredients supplier did not just add $33.5 million of quarterly revenue at a 14 percent gross margin. It manufactured a borrower that a Canadian chartered bank will lend to at commercial rates. If rescheduling stalls, that structure is the hedge.
What a broad Schedule III order is worth. H1 pretax income was $10.0 million and total tax expense was $30.4 million, an effective rate above 300 percent. At a normal 25 percent, tax would be $2.5 million and the half-year would have been positive $7.5 million rather than negative $20.4 million, a swing of about $27.9 million per half or roughly $56 million annualized, near 11 percent of market capitalization each year. Two caveats that most write-ups skip. First, the swing is mostly accrual, not cash, because Vireo is not paying most of it today. Second, prospective relief does not erase the $172.8 million already booked. The accrued position is settled with the IRS or in court, not by a rescheduling order.
Valuation: What It Is Worth If It Is a Normal Business
At $10.80 on August 14, 2026 (source: market quote), 48.82 million as-converted shares put market capitalization near $527 million. Add $322.4 million of debt, subtract $103.1 million of unrestricted cash, and enterprise value is roughly $746 million. Annualizing Q2 gives $837 million of revenue and $166 million of Adjusted EBITDA on the company's own non-GAAP reconciliation ($41.5 million for the quarter, against $32.7 million in Q1 when we last covered it).
| Lens | LQA EBITDA base | EV / EBITDA |
|---|---|---|
| Company Adjusted EBITDA | $166M | 4.5x |
| Less transaction expenses ($19.7M/qtr) | $87M | 8.6x |
| Less transaction expenses and stock comp | $57M | 13.0x |
EV of $746M throughout. Tier 1 MSO average EV/EBITDA was 4.7x on CY25 (SSC Advisors comps, priced May 29, 2026).
The band is the argument. On management's Adjusted EBITDA the stock sits at 4.5 times, right on the Tier 1 average, which is to say ordinary. But that number adds back $28.4 million of transaction expenses in six months, 38 percent of the $74.1 million of half-year Adjusted EBITDA, for a company that has closed or signed nine separate transactions since March. For a serial acquirer, deal costs are not one-time; they are the cost of the business model. Treat them as recurring and the multiple is 8.6 times, above the peer group. Include the net back-tax exposure of about $124 million in enterprise value and the same three lenses become roughly 5.2, 10.0 and 15.2 times. Tangible book, after removing $161.1 million of goodwill and $218.7 million of intangibles from $442.5 million of equity, is $62.7 million.
Pro forma does not obviously fix it. If the announced deals get the run rate above $1 billion at the Q2 Adjusted EBITDA margin of 19.8 percent, that is roughly $198 million of Adjusted EBITDA, against a share count nearer 65.6 million. At today's price the multiple lands in the same neighborhood. The dilution and the earnings arrive together.
Risks and Open Questions
The $172.8 million uncertain tax liability is current, and cash is $103.1 million. That is the risk that dominates all the others, and unlike a debt maturity it has no negotiated date. The Bridgewell credit facility, $22.0 million at 12 percent, matured on August 19, 2026, five days after this 10-Q was filed; the BMO revolver closed August 7 and presumably covers it, but the filing does not say so. The $49.0 million Perth seller note at 15 percent matures May 25, 2027, with two one-year extensions the company "intends to exercise" subject to a fee and no uncured default. The $106.7 million first lien matures July 31, 2028.
Every deal document is priced above the market. The Hawthorne shares were struck at a deemed $18.00 and marked at $11.79; PhytoNatural was struck at $18.60; the Deep Roots, Proper and Wholesome earnouts pay out at the higher of $31.50 or VWAP, and their clawback mechanics reference $15.60. The stock is $10.80. Contingent consideration of $36.5 million is now a current liability.
Related-party concentration deserves a look. Chicago Atlantic is the lender on four separate facilities in this filing, and the company paid Chicago Atlantic $6.0 million in the first half for underwriting, legal, accounting, data analytics and real estate services. CEO John Mazarakis is a partner of Chicago Atlantic Group, LP.
Two honest gaps. There is no going-concern language and no covenant-default disclosure anywhere in this filing, which cuts against the distress framing. And Vireo does not disclose same-store or organic retail metrics, so the "is the core growing" question cannot be answered from the 10-Q. What can be measured: Cannabis gross margin was 55.8 percent in Q1 and 51.5 percent in Q2, and wholesale fell from 23 percent of cannabis revenue to 12 percent. Neither is conclusive on a base that quadrupled through acquisition, and I will not pretend otherwise.
The Bottom Line
We said last quarter to watch the current income tax line, because that is where rescheduling shows up first. It moved barely at all as a share of revenue. What moved was the liability underneath it. Vireo is not the purest 280E victim in the coverage set; it is the operator that has been most willing to book the tax and not pay it, and it has used that float, plus its own equity, to buy more assets than anyone else in the sector. Both segments earn money at the segment line. The consolidated operating line does not, because deal costs are running at $19.7 million a quarter. The reported pretax profit is an artifact of a falling share price. And the most durable asset the roll-up bought this year may be the one nobody counts: a non-plant-touching subsidiary group that can borrow from Bank of Montreal at commercial rates while the cannabis side pays 15 percent.
The framework, not a recommendation: watch whether cash taxes paid start converging on tax expense, whether the uncertain tax liability keeps compounding, whether transaction expenses fall once the Ohio, Planet 13 and Cannabist deals close, and whether the non-cannabis credit facility gets used to refinance cannabis-side debt. Those four lines tell you whether this is a platform compounding or a float running.
No analyst wrote this. The finding is not a model or a channel check: it is three lines that were always sitting in the same filing, read next to each other. Current income tax expense is in the tax note. Income taxes paid, net, is one line in the supplemental cash flow disclosure. The uncertain tax liability is on the balance sheet. Nobody had to be clever, and nobody had to be right about the future. The same query runs against any filer's structured data, and a private company reporting in the same format is the same job.
Analysis built on the RoboSystems SEC Shared Repository: structured XBRL filing data for every public company that files. Every figure above traces to Vireo Growth's Form 10-Q for the quarter ended June 30, 2026 (accession 0001104659-26-097118) or the Form 10-K for fiscal 2025 filed March 17, 2026. Not investment advice. No price targets. No paid promotions. Run your own deep dives at robosystems.ai/pricing. New customers get 50% off your first month with code CANNABIS50.